Form 4: Eli Lilly Director Buys LLY Stock in $238K Transaction
Insider Transaction Report
Eli Lilly Director Jon R. Moeller acquired 233.271 shares of common stock at $1,021.7 per share on November 17, 2025, increasing his direct beneficial ownership to 304.271 shares.
Summary
- Jon R. Moeller, a Director of Eli Lilly & Co (LLY), acquired 233.271 shares of the company's common stock.
- The transaction occurred on November 17, 2025, at a price of $1,021.7 per share.
- Following this acquisition, Moeller's direct beneficial ownership of LLY common stock increased to 304.271 shares.
- The acquisition was made pursuant to a Rule 10b5-1 pre-arranged trading plan.
Sentiment
Score: 8
Explanation: The acquisition of company stock by a director, especially at a significant price and under a Rule 10b5-1 plan, typically indicates strong confidence in the company's future performance and valuation.
Positives
- A Director, Jon R. Moeller, acquired 233.271 shares of Eli Lilly & Co common stock, signaling confidence in the company's future prospects.
- The acquisition was made at a significant price of $1,021.7 per share, representing a substantial investment by the insider totaling approximately $238,300.
Future Outlook
The insider purchase by a Director may signal a positive long-term outlook for Eli Lilly & Co, as insiders typically buy when they believe the stock is undervalued or has significant growth potential.
Industry Context
Insider transactions, such as this director's stock acquisition, are closely watched by the market as they can provide insights into management's confidence in the company's performance relative to its peers in the pharmaceutical industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transaction was executed pursuant to a Rule 10b5-1 pre-arranged trading plan, which allows insiders to buy or sell shares at a predetermined time or price to avoid accusations of trading on material non-public information. | 11/17/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations, aligning insider transactions with corporate governance best practices. |
Related Party Transactions
- Jon R. Moeller, a Director of Eli Lilly & Co, acquired 233.271 shares of the company's common stock at $1,021.7 per share on November 17, 2025.
Stakeholder Impact
- Shareholders: May view the director's purchase as a positive signal of confidence in the company's future, potentially influencing investor sentiment and stock price.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of earliest transaction (acquisition of common stock) |
| 11/18/2025 | Signature date of the reporting person |
Recommendation
buyThe acquisition of company stock by a director, especially at a significant price and under a pre-arranged plan, typically indicates strong confidence in the company's future performance and valuation. While a single insider transaction does not guarantee future stock performance, it serves as a positive signal for investors, suggesting that management believes the stock is a good investment opportunity.
Keywords
Eli Lilly, LLY, insider trading, stock acquisition, director, common stock, Form 4, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.